Therapeutics for alcoholism: what's the future?

References

• Wutzke S E, Shiell A, Gomel M K, Conigrave K M. Cost effectiveness of brief interventions for reducing alcohol consumption. Soc Sci Med 2001; 52: 863–870
   PubMed Web of Science ®Google Scholar
• Ferguson R A, Goldberg D M. Genetic markers of alcohol abuse. Clin Chim Acta 1997; 257: 199–250
   PubMed Web of Science ®Google Scholar
• Mark T L, Kranzler H R, Song X, Bransberger P, Poole V H, Crosse S. Physicians' opinions about medications to treat alcoholism. Addiction 2003; 98: 617–626
   PubMed Web of Science ®Google Scholar
• Sinclair J D. Drugs to decrease alcohol drinking. Ann Med 1990; 22: 357–362
   PubMed Web of Science ®Google Scholar
• Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60: 92–99
   PubMed Web of Science ®Google Scholar
• Cowen M S, Rezvani A H, Jarrott B, Lawrence A J. Ethanol consumption by Fawn-Hooded rats following abstinence: effect of naltrexone and changes in mu-opioid receptor density. Alcohol Clin Exp Res 1999; 23: 1008–1014
   PubMedGoogle Scholar
• Brady K T, Sonne S, Anton R F, Randall C L, Back S E, Simpson K. Sertraline in the treatment of co-occurring alcohol dependence and post-traumatic stress disorder. Alcohol Clin Exp Res 2005; 29: 395–401
   PubMed Web of Science ®Google Scholar
• Torrens M, Fonseca F, Mateu G, Farre M. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend 2005; 78: 1–22
   PubMed Web of Science ®Google Scholar
• Pettinati H M, Volpicelli J R, Luck G, Kranzler H R, Rukstalis M R, Cnaan A. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol 2001; 21: 143–153
   PubMed Web of Science ®Google Scholar
• Nunes E V, Levin F R. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 2004; 291: 1887–1896
   PubMed Web of Science ®Google Scholar
• Mann K F. Acamprosate: clinical data. Drugs for relapse prevention of alcoholism, R Spanagel, K F Mann. Birkhäuser Verlag, Basel 2005; 85–94
   Google Scholar
• Cowen M S, Adams C, Kraehenbuehl T, Vengeliene V, Lawrence A J. The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system. Addiction Biol 2005; 10: 233–242
   PubMed Web of Science ®Google Scholar
• al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 1998; 22: 810–814
   PubMed Web of Science ®Google Scholar
• Saivin S, Hulot T, Chabac S, Potgieter A, Durbin P, Houin G. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 1998; 35: 331–345
   PubMed Web of Science ®Google Scholar
• Boismare F, Daoust M, Moore N, et al. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved?. Pharmacol Biochem Behav 1984; 21: 787–789
   PubMed Web of Science ®Google Scholar
• Le Magnen J, Tran G, Durlach J, Martin C. Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol 1987; 4: 97–102
   PubMed Web of Science ®Google Scholar
• Rimondini R, Arlinde C, Sommer W, Heilig M. Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol. FASEB J 2002; 16: 27–35
   PubMed Web of Science ®Google Scholar
• Cowen M S, Djouma E, Lawrence A J. The mGlu5 antagonist MTEP reduces ethanol self- administration in multiple strains of alcohol-preferring rats and regulates olfactory glutamatergic systems. J Pharmacol Exp Ther 2005; 315: 590–600
   PubMed Web of Science ®Google Scholar
• Chen F, Jarrott B, Lawrence A J. Up-regulation of cortical AMPA receptor binding in the Fawn-Hooded rat following ethanol withdrawal. Eur J Pharmacol 1999; 384: 139–146
   PubMedGoogle Scholar
• Bäckstrom P, Bachteler D, Koch S, Hyytia P, Spanagel R. mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behavior. Neuropsychopharmacology 2004; 29: 921–928
   PubMed Web of Science ®Google Scholar
• Chiamulera C, Epping-Jordan M P, Zocchi A, et al. Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 2001; 4: 873–874
   PubMed Web of Science ®Google Scholar
• Tessari M, Pilla M, Andreoli M, Hutcheson D M, Heidbreder C A. Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. Eur J Pharmacol 2004; 499: 121–133
   PubMed Web of Science ®Google Scholar
• Kenny P J, Boutrel B, Gasparini F, Koob G F, Markou A. Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. Psychopharmacology 2005; 179: 247–254
   PubMed Web of Science ®Google Scholar
• Lee B, Platt D M, Rowlett J K, Adewale A S, Spealman R D. Attenuation of behavioral effects of cocaine by the metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)-pyridine in squirrel monkeys: comparison with dizocilpine. J Pharmacol Exp Ther 2005; 312: 1232–1240
   PubMed Web of Science ®Google Scholar
• Breier A, Paul S M. The GABAA/benzodiazepine receptor: implications for the molecular basis of anxiety. J Psych Res 1990; 24(Suppl. 2)91–104
   Google Scholar
• Davidoff R A. Antispasticity drugs: mechanisms of action. Ann Neurol 1985; 17: 107–116
   PubMed Web of Science ®Google Scholar
• Lewohl J M, Wilson W R, Mayfield R D, Brozowski S J, Morrisett R A, Harris R A. G-protein-coupled inwardly rectifying potassium channels are targets of alcohol action. Nature Neurosci 1999; 2: 1084–1090
   PubMed Web of Science ®Google Scholar
• Stromberg M F. The effect of baclofen alone and in combination with naltrexone on ethanol consumption in the rat. Pharmacol Biochem Behav 2004; 78: 743–750
   PubMed Web of Science ®Google Scholar
• Liang J H, Chen F, Krstew E, et al. The GABAB receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcohol-preferring rats. Neuropharmacology 2006; 50: 632–639
   PubMed Web of Science ®Google Scholar
• Chalmers D T, Lovenberg T W, Grigoriadis D E, Behan D P, De Souza E B. Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol Sci 1996; 17: 166–172
   PubMed Web of Science ®Google Scholar
• Sarnyai Z, Shaham Y, Heinrichs S C. The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 2001; 53: 209–243
   PubMed Web of Science ®Google Scholar
• Lodge D J, Lawrence A J. The CRF1 receptor antagonist, antalarmin reduces volitional ethanol consumption in isolation-reared Fawn-Hooded rats. Neuroscience 2003; 117: 243–247
   PubMed Web of Science ®Google Scholar
• Lawrence A J, Parish C L, Chen F, et al. Chronic corticotropin-releasing factor type 1 receptor antagonism with antalarmin regulates the dopaminergic system of Fawn-Hooded rats. J Neurochem 2005; 94: 1523–1534
   PubMed Web of Science ®Google Scholar
• Broadbear J H, Winger G, Rice K C, Woods J H. Antalarmin, a putative CRH-R1 antagonist, has transient reinforcing effects in rhesus monkeys. Psychopharmacologia 2002; 164: 268–276
   Google Scholar
• Tanda G, Goldberg S R. Cannabinoids: reward, dependence and underlying neurochemical mechanisms – a review of recent preclinical data. Psychopharmacology 2003; 169: 115–134
   PubMedGoogle Scholar
• Gallate J E, Mallet P E, McGregor I S. Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats. Psychopharmacology 2004; 173: 210–216
   PubMed Web of Science ®Google Scholar
• Harris G C, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 2005; 437: 556–559
   PubMed Web of Science ®Google Scholar
• Boutrel B, Kenny P J, Specio S E, et al. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci USA 2005; 102: 19168–19173
   PubMed Web of Science ®Google Scholar
• Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol 2004; 40: 147–150
   PubMed Web of Science ®Google Scholar